No product-level FDA approval is required to sell a private label peptide firming serum in the United States as a cosmetic — but that does not mean the regulatory burden is zero, and the post-MoCRA landscape has added meaningful new obligations that brands must understand.
Cosmetics in the U.S. are regulated under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as amended by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). MoCRA, which went into full effect for most companies in 2024, introduced three key requirements that did not previously exist for small brands.
First, facility registration: any U.S. facility that manufactures or processes cosmetics for interstate commerce must register with the FDA biennially. If you are the brand owner and your contract manufacturer is FDA-registered, the manufacturer's registration covers production — but confirm this in your manufacturing agreement. If you import finished goods from overseas, your foreign supplier's facility must also be registered.
Second, product listing: each distinct cosmetic product (each SKU) must be listed with the FDA, including the facility where it is manufactured and the complete ingredient list. Product listings must be submitted initially and updated when formulas change.
Third, serious adverse event reporting: the brand's designated responsible person must report serious adverse events to the FDA within 15 days of receiving the report and maintain records for six years.
Beyond MoCRA, INCI labeling is required under the Fair Packaging and Labeling Act: every ingredient must appear on the label in descending order of concentration using the International Nomenclature of Cosmetic Ingredients name, not trade names. Peptide actives must appear under their INCI designation — for example, palmitoyl tripeptide-1, not "Matrixyl."
The critical compliance trap for peptide serum brands is claim language. Cosmetics may only claim to affect the appearance of skin. The moment your marketing copy claims that the product "rebuilds collagen," "reverses wrinkle formation at the cellular level," or produces any effect that goes beyond the outer layers of the skin, the FDA can classify the product as a drug — requiring a new drug application (NDA) and clinical trial data before sale. Stick to appearance-based claims: "visibly firms," "reduces the appearance of fine lines," "skin looks more youthful."
For brands planning EU distribution, a separate regulatory pathway applies under EC No 1223/2009, requiring a Cosmetic Product Safety Report, a responsible person established in the EU, CPNP notification, and a Product Information File maintained in the country of the responsible person. These are distinct from U.S. requirements and often require a third-party safety assessor.
Read the full guide on Private Label Peptide Firming Serum Manufacturer Low MOQ →